BIOMARKERS OF PROSTATE CANCER AND PREDICTING MORTALITY
- 专利权人:
- Jing MA
- 发明人:
- Jing MA
- 申请号:
- US13271164
- 公开号:
- US20120202888A1
- 申请日:
- 2011.10.11
- 申请国别(地区):
- US
- 年份:
- 2012
- 代理人:
- 摘要:
- Measurement of circulating C-peptide levels is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of fatal prostate cancer.
- 来源网站:
- 中国工程科技知识中心
相关发明人
相关专利
- How to use soluble CD24 to treat immune-related adverse events in cancer therapy
- METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES
- USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS A BIOMARKER FOR ANAPHYLAXIS
- METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES
- METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES